Synthetic lethality: A promising therapeutic strategy for hepatocellular carcinoma

被引：23

作者：

Tang, Linsong ^{[1
,2
]}

Chen, Ronggao ^{[1
,2
]}

Xu, Xiao ^{[1
,2
]}

机构：

[1] Zhejiang Univ, Affiliated Hosp 1, Dept Hepatobiliary & Pancreat Surg, Dept Surg,Sch Med, Hangzhou 310003, Peoples R China

[2] Minist Publ Hlth, NHFPC Key Lab Combined Multiorgan Transplantat, Hangzhou 310003, Peoples R China

来源：

CANCER LETTERS | 2020年 / 476卷

基金：

国家杰出青年科学基金;

关键词：

Hepatocellular carcinoma; Synthetic lethality; Screening technology; Genetic interactions; SENSITIZES CANCER-CELLS; ATR-INHIBITION; BETA-CATENIN; MYC; SCREEN; SORAFENIB; P53; VULNERABILITY; KINASE; TUMORS;

D O I：

10.1016/j.canlet.2020.02.016

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Hepatocellular carcinoma (HCC), the main cause of liver cancer-related death, is one of the main cancers in terms of incidence and mortality. However, HCC is difficult to target and develops strong drug resistance. Therefore, a new treatment strategy is urgently needed. The clinical application of the concept of synthetic lethality in recent years provides a new therapeutic direction for the accurate treatment of HCC. Here, we introduce the concept of synthetic lethality, the screening used to study synthetic lethality, and the identified and potential genetic interactions that induce synthetic lethality in HCC. In addition, we propose opportunities and challenges for translating synthetic lethal interactions to the clinical treatment of HCC.

引用

页码：120 / 128

页数：9

共 114 条

[71] CRISPR Screens Provide a Comprehensive Assessment of Cancer Vulnerabilities but Generate False-Positive Hits for Highly Amplified Genomic Regions [J].

Munoz, Diana M. ;

Cassiani, Pamela J. ;

Li, Li ;

Billy, Eric ;

Korn, Joshua M. ;

Jones, Michael D. ;

Golji, Javad ;

Ruddy, David A. ;

Yu, Kristine ;

McAllister, Gregory ;

DeWeck, Antoine ;

Abramowski, Dorothee ;

Wan, Jessica ;

Shirley, Matthew D. ;

Neshat, Sarah Y. ;

Rakiec, Daniel ;

De Beaumont, Rosalie ;

Weber, Odile ;

Kauffmann, Audrey ;

McDonald, E. Robert, III ;

Keen, Nicholas ;

Hofmann, Francesco ;

Sellers, William R. ;

Schmelzle, Tobias ;

Stegmeier, Frank ;

Schlabach, Michael R. .

CANCER DISCOVERY, 2016, 6 (08) :900-913

[72] Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR [J].

Neshat, MS ;

Mellinghoff, IK ;

Tran, C ;

Stiles, B ;

Thomas, G ;

Petersen, R ;

Frost, P ;

Gibbons, JJ ;

Wu, H ;

Sawyers, CL .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (18) :10314-10319

[73] Phase II Study of the Mitogen-Activated Protein Kinase 1/2 Inhibitor Selumetinib in Patients With Advanced Hepatocellular Carcinoma [J].

O'Neil, Bert H. ;

Goff, Laura W. ;

Kauh, John Sae Wook ;

Strosberg, Jonathan R. ;

Bekaii-Saab, Tanios S. ;

Lee, Ruey-min ;

Kazi, Aslamuzzaman ;

Moore, Dominic T. ;

Learoyd, Maria ;

Lush, Richard M. ;

Sebti, Said M. ;

Sullivan, Daniel M. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (17) :2350-2356

[74] TP53 Mutations in Human Cancers: Origins, Consequences, and Clinical Use [J].

Olivier, Magali ;

Hollstein, Monica ;

Hainaut, Pierre .

COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY, 2010, 2 (01) :a001008

[75] Synthetic Lethality of Combined Bcl-2 Inhibition and p53 Activation in AML: Mechanisms and Superior Antileukemic Efficacy [J].

Pan, Rongqing ;

Ruvolo, Vivian ;

Mu, Hong ;

Leverson, Joel D. ;

Nichols, Gwen ;

Reed, John C. ;

Konopleva, Marina ;

Andreeff, Michael .

CANCER CELL, 2017, 32 (06) :748-+

[76] An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice [J].

Podsypanina, K ;

Lee, RT ;

Politis, C ;

Hennessy, I ;

Crane, A ;

Puc, J ;

Neshat, M ;

Wang, H ;

Yang, L ;

Gibbons, J ;

Frost, P ;

Dreisbach, V ;

Blenis, J ;

Gaciong, Z ;

Fisher, P ;

Sawyers, C ;

Hedrick-Ellenson, L ;

Parsons, R .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (18) :10320-10325

[77] Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers [J].

Pourdehnada, Michael ;

Truitt, Morgan L. ;

Siddiqi, Imran N. ;

Ducker, Gregory S. ;

Shokat, Kevan M. ;

Ruggero, Davide .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2013, 110 (29) :11988-11993

[78]

Prochownik Edward V, 2010, Genes Cancer, V1, P650

[79] The Diverse Function of PD-1/PD-L Pathway Beyond Cancer [J].

Qin, Weiting ;

Hu, Lipeng ;

Zhang, Xueli ;

Jiang, Shuheng ;

Li, Jun ;

Zhang, Zhigang ;

Wang, Xu .

FRONTIERS IN IMMUNOLOGY, 2019, 10

[80] Loss of ARID1A expression sensitizes cancer cells to PI3K-and AKT-inhibition [J].

Samartzis, Eleftherios P. ;

Gutsche, Katrin ;

Dedes, Konstantin J. ;

Fink, Daniel ;

Stucki, Manuel ;

Imesch, Patrick .

ONCOTARGET, 2014, 5 (14) :5295-5303

← 3 4 5 6 7 8 9 10 11 12 →